CALL/AMGEN/450/0.1/16.01.26 | Real-time BOERSE MUENCHEN 06:26:45 2024-05-21 am EDT | ||
| 0.87 EUR | 0.00% |
|
| Current month | +145.07% | ||
| 1 month | +191.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 0.87 | 0.00% |
| 24-05-20 | 0.87 | +3.57% |
| 24-05-17 | 0.84 | -4.55% |
| 24-05-16 | 0.88 | -5.38% |
| 24-05-15 | 0.93 | +22.37% |
Real-time BOERSE MUENCHEN
Last update May 21, 2024 at 06:26 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GG323K |
| ISIN | DE000GG323K2 |
| Date issued | 2024-02-09 |
| Strike | 450 $ |
| Maturity | 2026-01-16 (606 Days) |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.97 € |
|---|---|
| Lowest since issue | 0.233 € |
| Spread | 0.1 € |
| Spread % | 10.31% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
314.5
USD
Average target price
316.1
USD
Spread / Average Target
+0.48%
- Stock Market
- Warrants
- Warrant
